AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claims 1-21 (Cancelled).

22. (Previously presented) A method of treating trypanosomiasis in a mammal, which comprises administering to a mammal in need thereof an effective amount of a medicinal product comprising a plant extract comprising one or more compounds of the formula (I):



(I)

wherein R_1, R_2, R_3, R_4, R_5, R_6, R_7 and R_8 represent, independently of one another:

a hydrogen atom;
a saturated or unsaturated, linear, branched or cyclic C_1-C_{12} alkyl group;
a halogen atom;
halo(C_1-C_{12})alkyl, wherein an alkyl group thereof is linear, branched or cyclic, and saturated or unsaturated;
hydroxyl;
nitro;
cyano;
mercapto;
carboxylic acid;
amide;
amine;
C_1-C_{12} alkoxy, wherein an alkyl group thereof is linear, branched or cyclic, and saturated or unsaturated;
C_1-C_{12} alkyl ester, wherein an alkyl group thereof is linear, branched or cyclic, and saturated or unsaturated,
secondary or tertiary alkylamide, wherein an C_1-C_{12} alkyl group(s) thereof is linear, branched or cyclic, and saturated or unsaturated;
secondary or tertiary alkylamide, wherein an C_1-C_{12} alkyl group(s) thereof is

linear, branched or cyclic, and saturated or unsaturated,
C_1-C_{12} alkylthio, wherein an alkyl group thereof is linear, branched or cyclic, and saturated or unsaturated;
C_2-C_6 heterocyclic group containing 1 to 4 hetero atoms selected from the group consisting of sulfur, nitrogen and oxygen;
a group -SO_2-NR'R" or a group –NR'-SO_2-R", in which R' and R" represent, independently of one another, a saturated or unsaturated, linear, branched or cyclic C_1-$C1_2$ alkyl group;

n represents 0 or 1;

R represents a saturated or unsaturated, linear, branched or cyclic C_1-C_{12} alkyl group; and

X represents an anion, which is either an inorganic or organic anion.

23. (Currently amended) The method of ~~Claim~~ claim 22, wherein the compound of formula (I) is canthin-6-one.

24. (Currently amended) The method of ~~Claim~~ claim 23, wherein the canthin-6-one is present in the form of an extract of a plant selected from the group consisting of *Ailanrhus altissima, Brucea antidysenterica, Eurycama harmandiana, Peganum nigellastrum, Zanthoxylum elephantiasis* and *Zanthoxylum chiloperone.*

25. (Currently amended) The method of ~~Claim~~ claim 24, wherein the canthin-6-one is present in the form of an extract of *Zanthoxylwn chiloperone* var. *angustifolium.*

26. (Currently amended) The method of ~~Claim~~ claim 22, for treating trypanosomiasis in a chronic phase or an acute phase.

27. (Currently amended) The method of ~~Claim~~ claim 22, for treating Chagas' disease.

28. (Currently amended) The method of ~~Claim~~ claim 22, for treating trypanosomiasis caused by *Trypanosoma brucei.*

29. (Currently amended) The method of ~~Claim~~ claim 22, for treating trypanosomiasis caused by *Trypanosoma cruzi.*

30. (Currently amended) The method of ~~Claim~~ claim 23, wherein the plant extract comprising canthin-6-one is obtained by a method comprising the first steps of grinding the dried bark of a trunk of *Zanthoxylum chiloperone* var. *angustifolium,* and then treating the ground dried bark with an aqueous alkaline solution.

31. (Currently amended) The method of ~~Claim~~ claim 30, wherein the plant extract comprising canthin-6-one is obtained by a method further comprising a second step comprising extracting the ground bark and aqueous alkaline solution with a chlorinated organic solvent.

32. (Currently amended) The method of ~~Claim~~ claim 22, wherein the medicinal product is administered at a dose of between about 0.01 and 100 mg/kg/d of compound of formula (I).

33. (Currently amended) The method of ~~Claim~~ claim 32, wherein the administered dose is between about 0.1 and 50 mg/kg/d.

34. (Currently amended) The method of ~~Claim~~ claim 33, wherein the administered dose is between about 1 and 20 mg/kg/d.

35. (Currently amended) The method of ~~Claim~~ claim 22, wherein the medicinal product is administered orally.

36. (Currently amended) The method of ~~Claim~~ claim 22, wherein the mammal is a human.

37. (Previously presented) A compound of the formula (I):



(I)

wherein R_1, R_2, R_3, R_4, R_5, R_6, R_7 and R_8 represent, independently of one another:
a hydrogen atom;
a saturated or unsaturated, linear, branched or cyclic C_1-C_{12} alkyl group;
a halogen atom;
halo(C_1-C_{12})alkyl, wherein an alkyl group thereof is linear, branched or cyclic, and saturated or unsaturated;
hydroxyl;
nitro;
cyano;
mercapto;
carboxylic acid;
amide;
amine;
C_1-C_{12} alkoxy, wherein an alkyl group thereof is linear, branched or cyclic, and saturated or unsaturated;
C_1-C_{12} alkyl ester, wherein an alkyl group thereof is linear, branched or cyclic, and saturated or unsaturated;
secondary or tertiary alkylamide, wherein an C_1-C_{12} alkyl group(s) thereof is linear, branched or cyclic, and saturated or unsaturated;

secondary or tertiary alkylamide, wherein an C_1-C_{12} alkyl group(s) thereof is linear, branched or cyclic, and saturated or unsaturated;
C_1-C_{12} alkylthio, wherein an alkyl group thereof is linear, branched or cyclic, and saturated or unsaturated;
C_2-C_6 heterocyclic group containing 1 to 4 hetero atoms selected from the group consisting of sulfur, nitrogen and oxygen;
a group $-SO_2$-NR'R" or a group -NR'-SO2-R", in which R' and R" represent, independently of one another, a saturated or unsaturated, linear, branched or cyclic C_1-C_{12} alkyl group;

n represents 0 or 1;

R represents a saturated or unsaturated, linear, branched or cyclic C_1-C_{12} alkyl group;

X represents an anion which is inorganic or organic anion, at least one of R_1, R_2, R_3, R_4, R_5, R_6, R_7 and R_8 being different from H, or else n=1;
and wherein;
when n= 0, $R_2 = R_3 = R_4 = R_5 = R_6$ =H and $R_8 = OCH_3$, then R_1 is different from –OH and $-OCH_3$;
when n = 0, $R_1 = R_2 = R_3 = R_5 = R_6 = R_7 = R_8$ = H, then R_4 is different from $-OCH_3$;
when n= 0, $R_1 = R_2 = R_3 = R_4 = R_5 = R_7 = R_8$ = H, then R_6 is different from –OH and $-OCH_3$;
when n = 0, $R_1 = R_2 = R_3 = R_4 = R_5 = R_8$ = H, then (R_6, R_7) is different from ($-OCH_3$, $-OCH_3$);
when n = 0, $R_2 = R_3 = R_4 = R_5 = R_6 = R_7 = R_8$ H, then R_1 is different from –OCH3;
when n = 0, $R_1 = R_2 = R_3 = R_4 = R_5 = R_6 = R_8$, then R_7 is different from –OH;

and

R_7 is different from $-OCH_3$;
when n 0, $R_2 = R_3 = R_4 = R_5 = R_6 = R_7$ = H and $R_2 = -OCH_3$, then R_8 is different from –OH; and
when n = 1, X = Cl, R = CH_3, $R_1 = R_2 = R_5 = R_6 = R_7 = R_8$ = H and R_3 = $-OCH_3$ then R_4 is different from –OH.

38. (Currently amended) The compound of ~~Claim~~ claim 36, wherein X^- is selected from the group consisting of Cl^-, Br^-, I^-, S^-, PO_3^-, NO_3^-, acetate, oxalate, tartrate, succinate, maleate, fumarate, gluconate, citrate, malate, ascorbate and benzoate.

39. (Currently amended) The compound of ~~Claim~~ claim 34, wherein one or more of the conditions below are satisfied;

a) R_3 represents an NH_2 group or a C_1-C_{12} alkylamine group or a C_3-C_{12} alkylamide group or a C_2-C_6 heterocycle comprising at least one amine group;

b) R_4 represents a hydroxyl group or a C_1-C_{12} alkoxy group; or

c) $R_1=R_2=R_5=R_7=R_8=H$.

40. (Currently amended) The compound of ~~Claim~~ claim 36, wherein one or more of the conditions below are satisfied:

a) R_3 represents an NH_2 group or a C_1-C_6 alkylamine group or a C_1-C_6 alkylamide group or a C_2-C_6 heterocycle comprising at least one amine function;

b) R_4 represents a hydroxyl group or a C_1-C_6 alkoxy group; or

c) $R_1=R_2=R_5=R_6=R_7=R_8=H$.

41. (Currently amended) The compound of ~~Claim~~ claim 36, wherein one or more of the conditions below are satisfied:

a) R_3 represents an NH_2 group;

b) R_4 represents an OCH_3 group; or

c) $R_1=R_2=R_5=R_6=R_7=R_8=H$.

42. (Currently amended) The compound of ~~Claim~~ claim 36, wherein $R_1 = R_2 = R_3 = R_4 = R_5 = R_6 = R_7 = R_8 = H$ and $n = 1$, and R is a C_1-C_6 alkyl group.

43. (Currently amended) The compound of ~~Claim~~ claim 36, which is: 4-aminocanthin-6-one.

44. (Currently amended) The compound of ~~Claim~~ claim 36, which is N-methylcanthin-6-one iodide.

45. (Currently amended) A pharmaceutical composition, which comprises one or more compounds of ~~Claim~~ claim 37, and a carrier.

46. (Previously presented) A pharmaceutical composition, which comprises a plant extract obtained from Ailanthus altissima, Brucea antidysenteria, Eurycoma, harmandiana, Peganum nigellastrum, Zanthoxylum elephantiasis and Zanthoxylan chiloperone; and a carrier.

47. (Currently amended) The pharamaceutical composition of ~~Claim~~ claim 46, wherein said plant extract comprises canthin-6-one, 4-aminocanthin-6-one or N-methylcanthin-6-one iodide or a mixture thereof.

48. (Previously presented) A method of treating trypariosomiasis in a mammal, which comprises administering to a mammal in need thereof an effective amount of a plant or an extract thereof selected from the group of *Ailanthus altissima, Brucea antidysenteria, Eurycoma, harmandiana, Peganum nigellastrum, Zanthoxylum elephantiasis and Zanthoxylan chiloperone;* and a carrier.

49. (New) The method of claim 22, wherein for said one or more compounds of the formula (I), n is 0, and one of R_3 or R_4 is other than –H.

50. (New) The compound of claim 37, wherein for said one or more compounds of the formula (I), n is 0, and one of R_3 and R_4 is other than –H.

51. (New) The composition of claim 45, wherein for said one or more compounds of the formula (I), n is 0, and one of R_3 and R_4 is other than –H.